S
Shanghai Likai Technology
Health Tech & Medtech · Minhang District, China · Founded 2019
Clinically proven neurovascular interventional and implantable medical devices MoreLess
Kai MedTech Inc., also known as Shanghai Likai Technology, develops and commercializes interventional and implantable medical devices for treating neurovascular diseases. The company was founded in 2019 by Chairman Jianbing Wang. Wang previously founded MicroVention in 1997, which was later acquired by Terumo Corporation.
Kai MedTech operates with a vision of creating an innovative medical device platform. It maintains a portfolio of products and has established three research and development and manufacturing sites located in Lake Forest, California, USA; Shanghai, China; and Hangzhou, China. The company's business model is centered on the development and sale of these medical devices to the healthcare sector.
As of March 31, 2023, the company has commercialized nine NMPA Class III products in China and one product with US FDA 510(k) clearance. Its product pipeline includes devices like the ReviveFlow™ Revascularization Device and the Perfiller® Embolic Coil, designed for procedures such as mechanical thrombectomy and aneurysm treatment.
Keywords: neurovascular devices, medical technology, interventional neurology, implantable devices, thrombectomy, aneurysm treatment, NMPA, FDA 510(k), embolic coils, revascularization
Company overview
Shanghai Likai Technology company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2019
- Headquarters
- Minhang District, China
- Employees
- 8
- Open positions
- None listed
- Dealroom signal
- 80.8
Valuation & funding
Shanghai Likai Technology funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES D✓Equity / VC | Jul 2026 | $69M | $275M | Shenzhen Capital Group · Huatai Zijin Investment | ↗ |
| SERIES D✓Equity / VC | Feb 2026 | — | — | Guoxin Investment | ↗ |
| SERIES C✓Equity / VC | Jan 2024 | $28M | $110M | Guoxin Investment · Wuxi Innovation Investment Group | ↗ |
| SERIES BEquity / VC | Aug 2021 | $0 | — | Undisclosed | ↗ |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 6 |
| 2025 | 8 |
| 2024 | 6 |
| 2023 | 9 |
| 2022 | 8 |
Growth signals
Shanghai Likai Technology website traffic
Latest recorded traffic for Shanghai Likai Technology is 20K monthly website visits, up 5614.3% over the last three months. Shanghai Likai Technology's team grew 0% over the past year.
Comparisons
Shanghai Likai Technology compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Shanghai Likai Technology's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Shanghai Likai Technology has talent and traffic
In the news
Latest news about Shanghai Likai Technology
Recent press, funding announcements, and product moves mentioning Shanghai Likai Technology — open to read from the original sources.
Market sentiment
What the market is saying about Shanghai Likai Technology
An AI-synthesized read of the highest-engagement posts about Shanghai Likai Technology on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shanghai Likai Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.